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1. Introduction 
The alarm of a drug antimicrobial resistance reported case 
reminds scientists the powerful evolution machinery in nature. 
Infections with resistant organisms are very difficult to treat, 
requiring costly and sometimes toxic alternatives. Bacteria, 
viruses, fungi, and parasites can cause disease among humans, 
other animals, and plants and have the ability to develop resistance 
to the drugs created against them. To face this problem when 
vaccines are not available, the development of new drugs as well 
as new diagnostic tests to track the origin and mechanism of 
resistance are prioritary. 
Drug targets are usually proteins but are in some cases small 
regions of DNA or RNA. Synthetic nucleotides and nucleosides 
are currently being used to modify natural DNA/RNA sequences, 
altering specifically gene expression.1 With this idea commercially 
available antiviral agents such as, for example, AZT, ribavirin, 
lamivudine, emtricitabine and stavudine incorporate mimetic 
heterocycles at the 2 position.2,3 In addition, another different 
(non-commercial) compounds have shown interesting antiviral 
properties due to the presence of substituted 
pyridine/quinoline/quinazoline nucleus4 or substituted 
indole/benzimidazole rings.5 The synthesis of all these compounds 
require several steps and occasionally chemical yields are low. 
 
Figure 1. Synthetic nucleosides possessing high antiviral 
inhibition. 
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A multicomponent 1,3-dipolar cycloaddition between heterocyclic aldehydes, amino esters and 
dipolarophiles is efficiently promoted by silver acetate as catalyst, and depending on the nature of 
the heterocycle and its reactivity the reaction requires 70 °C or rt to complete. Selected 
pharmacophores anchored to a formyl group are chromone, 5-methoxyindole, pyridoxal 
surrogates and a very attractive uracyl derivative. The preference of each tested amino esters 
towards different dipolarophiles is discussed. At the end, a selective reduction of the ester group 
allows to obtain a very interesting dideoxiazanucleoside derivative.  
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In this work, the synthesis of prolinates and pseudo-
azanucleosides bearing a mimetic nucleo-base anchored in the 
strategic position 5 and a nitrogen atom instead of the furan oxygen 
is designed.6 The multicomponent7,8 1,3-dipolar cycloaddition 
(1,3-DC)9 between heterocyclic aldehydes, amino esters and the 
corresponding dipolarophile was choiced as straightforward way10 
to access this new family of compounds 8.11 Apart from 
conventional hydrogen bonds between heterocycle and the genetic 
material of the microorganism, new additional biological 
interactions through the proline nitrogen atom can be envisaged. 
 
2. Results and Discussion 
This operationally simple multicomponent 1,3-DC started with 
the selection of four biologically attractive commercially available 
heterocyclic aldehydes 9-12 (Figure 2) based on the important role 
in nature of chromones,12 5-methoxyindole,13 pyridoxal14 and 
uracyl15 surrogates.  
 
 
Figure 2. Commercially available formylheterocycles used in this 
work.  
 
The optimization of the reaction was very simple16 and only 
solvents (DCM, EtOH, PhMe, THF) and temperature (rt-110 ºC 
range) were studied for all the formylheterocycles involved, silver 
acetate being necessary for the completion of the reaction. In 
general, to the solution (or suspension) of the free amino ester (or 
its hydrochloride), the aldehyde and triethylamine (1.1 equiv) in 
the corresponding solvent, the dipolarophile and silver acetate (5 
mol%) were added in this order. Thus, 3-formyl-6-
methylchromone (9) was tested in the presence of phenylalanine 
ethyl ester hydrochloride and N-methylmaleimide (NMM) as 
dipolarophile. Whilst the reaction did not occur neither at room 
temperature nor 70 °C in toluene, the expected endo-cycloadduct 
8aa was obtained in 75% yield and 92:8 endo:exo ratio, after flash 
chromatography when the reaction was performed in refluxing 
ethanol (the best solvent for these series of compounds) for 10 h 
(Scheme 1). N-Benzylmaleimide (NBM) and methyl acrylate also 
gave good yields of cycloadducts 8ab (65%) and 8ac (76%), 
respectively (Scheme 1). Alanine methyl ester hydrochloride was 
allowed to react under this reaction conditions with maleimides 
giving rise to polycyclic compounds endo-8ad and endo-8ae in 70 
and 65% yields (Scheme 1). Unfortunately, the in situ generated 
imine from glycine methyl ester hydrochloride and aldehyde 9 
afforded the expected cycloadduct in very low yield (<10% by 
analysis of 1H NMR spectra of the crude mixture) unpurified with 
decomposed compounds and a noticeable amount (approx. 20% by 
1H NMR) of several stereoisomers of imidazolidine 13a as a result 
of the reaction of the imine with itself (Scheme 1). Compouds 8ab-
8ae were isolated as unique endo-diastereoisomer (>95:5 dr). 
 
 
 
Scheme 1. Synthesis of compound 8a series bearing 4-
chromenone nucleus. 
 
5-Methoxyindole-3-carbaldehyde (10) behaved similarly to 
chromone 9. The cleanest reaction occurred in toluene at 70 °C in 
the presence of α-substituted amino esters with maleimides, 
triethylamine (1.1 equiv) and silver acetate (5 mol%) (Scheme 2). 
Thus, the combination with NMM and NBM with phenylalanine 
ethyl ester hydrochloride gave endo-cycloadducts 8ba and 8bb in 
moderate yield (52 and 55%, respectively). Alanine methyl ester 
hydrochloride also underwent 1,3-DC under standard conditions 
with NMM furnishing product endo-8bc in 60% yield (Scheme 2). 
Glycine methyl ester hydrochloride gave the corresponding 
mixture of stereoisomeric imidazolidines 13b (not drawn, approx. 
20% by 1H NMR) together with decomposed compounds and a 
small amount of the desired cycloadduct (<10% by analysis of 1H 
NMR spectra of the crude mixture). Acrylates are not appropriate 
dipolarophiles in this particular transformation. As well as 
occurred in the last series, compouds 8ba-8ac were isolated as 
unique endo-diastereoisomer (>95:5 dr). 
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Scheme 2. Synthesis of compound 8b series bearing 5-
methoxyindole nucleus. 
 
Pyridoxal hydrochloride (11·HCl) was the first example of a 
formylheterocycle able to react with glycine methyl ester 
hydrochloride under the standard reaction conditions in refluxing 
ethanol (best solvent). When this two reagents were combined 
with triethylamine (2.2 equiv), NMM and silver acetate (5 mol%) 
in refluxing ethanol, cycloadduct endo-8ca was isolated in 96% 
yield (Scheme 3) and no traces of imidazolidine 13c were detected. 
Phenylalanine ethyl ester hydrochloride reacted with maleimides 
producing endo-8cb and endo-8cc in excellent yields and more 
than 95:5 endo:exo ratio (Scheme 3). Ethyl acrylate was required 
in order to prevent transesterification from the solvent. The 
reaction with 11·HCl, the already mentioned acrylate and ethyl 
phenylalaninate furnished molecule 8cd in very high yield (92%) 
and high diastereomeric ratio (90:10 endo:exo) (Scheme 3). It is 
noteworthy that the two hydroxyl groups of the pyridoxal 11 were 
not protected previously to the cycloaddition, which demonstrated 
a high functional group tolerance. 
 
 
 
Scheme 3. Synthesis of compound 8c series bearing a pyridoxal 
surrogate nucleus. 
 
The 1,3-DC involving 5-formyluracil (12) are perhaps the most 
attractive series because it resembles the natural uridine 
nucleoside. The multicomponent reaction was implemented at 
room temperature in a different way to the reactions run before. 
Toluene was the most appropriate solvent. Glycine methyl ester 
hydrochloride reacted with maleimides and 12 to give endo-
cycloadducts 8da and endo-8db in 82 and 88% yield, respectively 
(Scheme 4, eq. 1). When phenylalanine ethyl ester was employed 
as free amine, base was not needed and the reaction was completed 
in 10 h. NMM, NBM and ethyl acrylate were appropriate 
dipolarophiles to access the interesting azanucleosidic agents 8dc-
8de (Scheme 4, eq. 2). The high yields achieved in all these 
examples were obtained after recrystallization/precipitation from 
warm ethanol taking advantage of the poor solubility of molecules 
8da-8de. The preparation of compound endo-8da was also 
attempted in a 1.5 g scale obtaining the same chemical yield. All 
of the cycloadducts containing the uracyl moiety were isolated as 
unique endo-diastereoisomers (>95:5 dr). 
 
 
 
 
Scheme 4. Synthesis of compound 8d series bearing a uracil 
nucleus. 
 
The relative configuration of products 8 were determined by 
selective nOe experiments identifying clearly in the most 
representative examples of each series the all cis-arrangement 
typical of the major endo-approach of the dipolarophile to the 
intermediate W-shape conformer of the azomethine ylide.  
Moreover, all compounds described in this article are being tested 
as potential antibacterial, antitumor and antiviral agents. 
To demonstrate the utility of this methodology the preparation 
of more similar structures to natural scaffolds such as endo-14dc 
was achieved by selective reduction of the ester group of the uracyl 
derivative endo-8dc in good yield (80%) using NaBH4 in methanol 
under reflux of THF for 10 h (Scheme 5).17,18 
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Scheme 5. Synthesis of mimetic dideoxiazanucleoside endo-14dc. 
 
3. Conclusions 
According to all these results we can conclude that a large 
family of azanucleosides can be efficiently and easily prepared in 
a multicomponent process from readily accessible starting 
compounds. The versatility of the 1,3-DC has been demonstrated 
once more allowing the presence of many functional groups 
ensuring a 2,4,5-cis-arrangement or all. Among this, the 
operational simplicity of this procedure permits its implementation 
in a larger scale. A reduction of the ester group can be the key to 
new family of potential drugs whose study of activity is in their 
infancy. The asymmetric 1,3-DC version of these transformations 
is a difficult task and are currently underway.  
 
4. Experimental Section 
4.1. General 
All commercially available reagents and solvents were used 
without further purification, only aldehydes were also distilled prior 
to use. Analytical TLC was performed on Schleicher & Schuell 
F1400/LS 254 silica gel plates, and the spots were visualised under 
UV light (λ = 254 nm). Flash chromatography was carried out on 
handpacked columns of Merck silica gel 60 (0.040-0.063 mm). 
Melting points were determined with a Reichert Thermovar hot plate 
apparatus and are uncorrected. The structurally most important peaks 
of the IR spectra (recorded using a Nicolet 510 P-FT) are listed and 
wave numbers are given in cm-1. NMR spectra were obtained using a 
Bruker AC-300 or AC-400 and were recorded at 300 or 400 MHz for 
1H NMR and 75 or 100 MHz for 13C NMR, using CDCl3 or DMSO-
d6 as solvent and TMS as internal standard (0.00 ppm). The following 
abbreviations are used to describe peak patterns where appropriate: s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet or 
unresolved and br s = broad signal. All coupling constants (J) are given 
in Hz and chemical shifts in ppm. 13C NMR spectra were referenced 
to CDCl3 at 77.16 ppm. DEPT-135 experiments were performed to 
assign CH, CH2 and CH3. Low-resolution electron impact (EI) mass 
spectra were obtained at 70 eV using a Shimadzu QP-5000 by 
injection or DIP; fragment ions in m/z are given with relative 
intensities (%) in parentheses. High-resolution mass spectra (HRMS) 
were measured on an instrument using a quadrupole time-of-flight 
mass spectrometer (QTOF) and also through the electron impact mode 
(EI) at 70 eV using a Finnigan VG Platform or a Finnigan MAT 95S. 
Microanalyses were performed in a Thermo Finnigan Flash 1112 
Series. 
 
4.2. General procedure for the synthesis of products 8a and 8b. 
To a stirred solution of amino ester hydrochloride (1.1 equiv, 0.6 
mmol) in EtOH (3 mL, for 8a) or toluene (3 mL, for 8b), aldehyde (1 
equiv, 0.5 mmol) was added. After that, Et3N (1.1 equiv, 70 µL), the 
dipolarophile (1 equiv, 0.5 mmol) and AgOAc (5 mol%) were added 
in this order. The reaction mixture was stirred overnight at 70 °C. The 
solvent was evaporated under reduced pressure. The crude mixture 
was extracted with ethyl acetate and washed with brine. The organic 
phase was dried (MgSO4), filtrated and evaporated. The 
corresponding pyrrolidines were obtained in good yields after 
purification by flash chromatography (Hex/AcOEt).  
 
4.2.1. (1S*,3R*,3aS*,6aR*)-Ethyl 1-benzyl-5-methyl-3-(6-methyl-4-
oxo-4H-chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-
carboxylate (8aa): White solid, (178 mg, 75% yield). IR (neat) ʋmax: 
730, 1098, 1288, 1436, 1484, 1642, 1703, 1736, 2959 cm-1. 1H NMR 
(300 MHz, CDCl3) δ: 1.41 (t, J = 7.2 Hz, 3H), 2.45 (s, 3H), 2.84 (s, 
3H), 3.19 (d, J = 13.7 Hz, 1H), 3.48 (d, J = 7.2 Hz 1H), 3.57 (d, J = 
13.7 Hz, 1H), 3.75 (br s, 1H), 4.35 (q, J = 8.5 Hz, 2H), 4.90 (d, J = 9.0 
Hz, 1H), 7.20-7.26 (m, 5H), 7.33 (d, J = 8.6 Hz, 1H), 7.48 (dd, J = 8.6, 
2.3 Hz, 1H) 7.96 (s, 1H), 8.01 (d, J = 0.9 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ: 14.1, 21.0, 25.1, 40.1, 47.5, 54.1, 62.0, 71.3, 77.3, 118.0, 
123.0, 125.1, 127.6, 128.9, 129.6, 129.8, 134.9, 135.2, 135.4, 152.9, 
154.7, 170.3, 174.6, 175.2, 177.6. LRMS (EI): m/z = 474 (M+, >1%), 
401 (14), 384 (23), 383 (100), 337 (34), 252 (14), 91 (22). HRMS (EI): 
calcd. for [C27H26N2O6] 474.1791; found 474.1781. 
 
4.2.2. (1S*,3R*,3aS*,6aR*)-Ethyl 1,5-dibenzyl-3-(6-methyl-4-oxo-4H-
chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-
carboxylate (8ab): Yellow solid, (179 mg, 65% yield). IR (neat) ʋmax: 
709, 1173, 1345, 1398, 1484, 1640, 1707, 1736, 2933 cm-1. 1H NMR 
(300 MHz, CDCl3) δ: 1.42 (t, J = 7.2 Hz, 3H), 2.48 (s, 3H), 3.15 (d, J 
= 13.7 Hz, 1H), 3.47 (d, J = 7.7 Hz, 1H), 3.59 (d, J = 13.7 Hz, 1H), 
3.87 (d, J = 7.6 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 4.54 (q, J = 14.1 Hz, 
2H), 4.98 (d, J = 8.8 Hz, 1H), 7.16-7.32 (m, 11H), 7.49 (dd, J = 8.6, 
2.1 Hz, 1H) 7.62 (s, 1H), 8.06 (d, J = 2.2 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ: 14.2, 21.0, 40.1, 42.5, 46.9, 53.9, 61.8, 71.1, 77.3, 117.9, 
123.0, 125.2, 127.5, 127.9, 128.5, 128.6, 128.7, 128.9, 129.6, 135.0, 
135.1, 135.2, 135.7, 152.7, 154.6, 170.5, 174.2, 174.9, 177,4. LRMS 
(EI): m/z = 550 (M+, >1%), 447 (16), 460 (31), 459 (100), 413 (46), 
252 (26), 91 (92). HRMS (EI): calcd. for [C33H30N2O6] 550.2104; 
found 550.2078. 
 
4.2.3. (2R*,4S*,5R*)-2-Ethyl 4-methyl 2-benzyl-5-(6-methyl-4-oxo-
4H-chromen-3-yl)pyrrolidine-2,4-dicarboxylate (8ac): Yellow oil, 
(170 mg, 76% yield). IR (neat) ʋmax: 1198, 1437, 1485, 1619, 1645, 
1733, 2251, 2950, 2981, 3339 cm-1. 1H NMR (300 MHz, CDCl3) δ: 
1.25 (t, J = 7.1 Hz, 3H), 2.26 (dd, J = 13.6, 7.7 Hz, 1H), 2.42 (s, 3H), 
2.75 (dd, J = 13.6, 4.7 Hz, 1H), 3.01 (d, J = 13.4 Hz, 1H), 3.18 (d, J = 
13.4 Hz, 1H), 3.31 (s, 3H), 3.54 (td, J = 7.5, 4.8 Hz, 1H), 4.18 (tq, J = 
7.2, 3.4 Hz, 3H), 4.79 (d, J = 7.5 Hz, 1H), 7.14-7.33 (m, 5H), 7.32 (d, 
J = 8.6 Hz, 1H), 7.45 (dd, J = 8.6, 2.0 Hz, 1H), 7.97 (d, J = 1.3 Hz, 
1H), 8.08 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 14.2. 21.0, 38.9, 45.0, 
47.1, 51.5, 56.5, 61.3, 69.3, 117.9, 123.1, 125.1, 127.0, 128.2, 128.3, 
130.0, 135.0, 135.1, 136.5, 153.5, 154.6, 173.1, 174.8, 177.2. LRMS 
(EI): m/z = 449 (M+, >1%), 376 (27), 359 (21), 358 (100), 280 (15), 
259 (52), 252 (26), 226 (15), 91 (33). HRMS (EI): calcd. for 
[C26H27NO6] 449.1838; found 449.1840. 
 
4.2.4. (1S*,3R*,3aS*,6aR*)-Methyl 1,5-dimethyl-3-(6-methyl-4-oxo-
4H-chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-
carboxylate (8ad): Pale brown solid, (134 mg, 70% yield). IR (neat) 
ʋmax: 709, 1173, 1345, 1398, 1484, 1640, 1707, 1736, 2933. 1H NMR 
(300 MHz, CDCl3) δ: 1.70 (s, 3H), 2.44 (s, 3H), 2.86 (s, 3H), 3.35 (d, 
J = 7.7 Hz, 1H), 3.78 (t, J = 8.2 Hz, 1H), 3.88 (s, 3H), 4.88 (d, J = 8.9 
 5 
Hz, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.49 (dd, J = 8.6, 2.2 Hz, 1H), 7.95 
(dd, J = 2.0, 1.0 Hz, 1H), 8.08 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 
21.1, 23.0, 25.4, 48.2, 53.4, 55.8, 57.6, 68.5, 118.1, 123.1, 125.1, 
135.7, 135.9, 154.2, 154.8, 171.2, 174.5, 175.0, 178.5. LRMS (EI): 
m/z = 384 (M+, >1%), 369 (18), 326 (20), 325 (100), 273 (19), 266 
(26), 213 (23), 119 (21). HRMS (EI): calcd. for [C20H20N2O6] 
384.1321; found 384.1305.  
4.2.5. (1S*,3R*,3aS*,6aR*)-Methyl 5-benzyl-1-methyl-3-(6-methyl-4-
oxo-4H-chromen-3-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-
carboxylate (8ae): Yellow solid, (150 mg, 65% yield). IR (neat) ʋmax: 
700, 1170, 1344, 1399, 1485, 1640, 1705, 1740, 2952. 1H NMR (300 
MHz, CDCl3) δ: 1.72 (s, 3H), 2.46 (s, 3H), 3.35 (d, J = 7.9 Hz, 1H), 
3.79 (d, J = 8.6 Hz, 1H), 3.85 (s, 3H), 4.50 (d, J = 4.8 Hz, 1H), 5.01 
(d, J = 6.3 Hz, 1H), 7.26-7.30 (m, 6H), 7.34 (d, J = 8.6 Hz, 1H), 7.50 
(dd, J = 8.6, 2.0 Hz, 1H), 7.95 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 
21.0, 22.8, 42.9, 47.6, 53.3, 55.2, 56.7, 68.2, 118.0, 122.9, 125.1, 
128.0, 128.5, 128.7, 128.9, 135.4, 135.6, 135.7, 154.2, 154.7, 171.0, 
174.0, 174.6, 178.2. LRMS (EI): m/z = 460 (M+, >1%), 445 (24), 402 
(27), 401 (100), 273 (33), 266 (70), 240 (28), 213 (26), 91 (74). HRMS 
(EI): calcd. for [C26H24N2O6] 460.1634; found 460.1629. 
 
4.2.6. (1S*,3R*,3aS*,6aR*)-Ethyl 1-benzyl-3-(5-methoxy-1H-indol-3-
yl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
(8ba): Grey solid, (119 mg, 52% yield). IR (neat) ʋmax: 703, 1214, 
1381, 1283, 1437, 1485, 1704, 2938, 3375. 1H NMR (300 MHz, 
CDCl3) δ: 1.26 (t, J = 7.2 Hz, 3H), 2.98 (s, 3H), 3.30 (d, J = 13.4 Hz, 
1H), 3.37-3.44 (m, 1H), 3.48-3.54 (m, 1H), 3.51 (d, J = 13.7 Hz, 1H), 
3.82 (s, 3H), 4.16 (q, J = 7.2 Hz, 2H), 4.86 (d, J = 6.4 Hz, 1H), 6.85 
(dd, J = 8.9, 2.4 Hz, 1H), 7.16 (s, 1H), 7.22-7.36 (m, 7H), 8.18 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ: 14.1, 25.2, 40.0, 48.9, 54.0, 55.7, 56.5, 
62.5, 71.5, 100.3, 112.3, 112.7, 126.0, 127.8, 128.3, 128.9, 130.1, 
131.1, 131.5, 134.7, 153.9, 174.2, 174.5, 175.1. LRMS (EI): m/z = 461 
(M+, >1%), 388 (67), 371 (23), 370 (100), 350 (28), 212 (20), 185 (30), 
147 (22), 91 (27). HRMS (EI): calcd. for [C26H27N3O5] 461.1951; 
found 461.1941. 
 
4.2.7. (1S*,3R*,3aS*,6aR*)-Ethyl 1,5-dibenzyl-3-(5-methoxy-1H-
indol-3-yl)-4,6- dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
(8bb): Brown solid, (148 mg, 55% yield). IR (neat) ʋmax: 701, 1174, 
1211, 1396, 1704, 2932, 3348. 1H NMR (300 MHz, CDCl3) δ: 1.43 (t, 
J = 7.2 Hz, 3H), 3.18 (d, J = 13.5 Hz, 1H), 3.48-3.60 (m, 3H), 3.87 (s, 
3H), 4.32 (d, J = 14.1 Hz, 1H), 4.39 (qd, J = 7.2, 1.0 Hz, 2H), 4.47 (d, 
J = 14.1 Hz, 1H), 5.17 (d, J = 8.9 Hz, 1H), 6.76 (d, J = 2.5 Hz, 1H), 
6.84 (dd, J = 8.9, 2.5 Hz, 1H), 7.22-7.30 (m, 12H), 8.36 (s, 1H). 13C 
NMR (75 MHz, CDCl3) δ: 14.2, 40.1, 42.6, 49.0, 54.9, 52.2, 55.9, 
61.7, 71.1, 100.9, 111.8, 112.2, 112.4, 127.4, 127.8, 128.5, 128.8, 
128.9, 129.8, 135.4, 135.7, 153.9, 171.2, 174.7, 175.6. LRMS (EI): 
m/z = 537 (M+, >1%), 464 (13), 447 (16), 446 (57), 444 (20), 351 (23), 
350 (100), 276 (29), 212 (22), 185 (37), 158 (21), 91 (65). HRMS (EI): 
calcd. for [C32H31N3O5] 537.2264; found 537.2244. 
 
4.2.8. (1S*,3R*,3aS*,6aR*)-Methyl-3-(5-methoxy-1H-indol-3-yl)-1,5-
dimethyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
(8bc): Brown solid, (110 mg, 60% yield). IR (neat) ʋmax: 1289, 1439, 
1702, 1751, 2957, 3265. 1H NMR (300 MHz, CDCl3) δ: 1.62 (s, 3H), 
2.72 (s, 3H), 3.33 (d, J = 7.6 Hz, 1H), 3.57 (dd, J = 9.1, 7.5 Hz, 1H), 
3.82 (s, 3H), 3.89 (s, 3H), 5.04 (d, J = 9.1 Hz, 1H), 6.80 (dd, J = 8.8, 
2.4 Hz, 1H), 7.00 (d, J = 2.4 Hz, 1H), 7.05 (d, J = 2.1 Hz, 1H), 7.15 
(d, J = 8.8 Hz, 1H), 8.45 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 23.9, 
25.1, 50.4, 52.8, 55.8, 56.5, 56.9, 67.4, 100.8, 111.6, 112.4, 112.5, 
123.4, 126.5, 131.8, 154.0, 173.2, 175.3, 176.3. LRMS (EI): m/z = 371 
(M+, >1%), 269 (20), 261 (16), 260 (100), 200 (62), 185 (63), 169 (29), 
159 (40). HRMS (EI): calcd. for [C19H21N3O5] 371.1481; found 
371.1473. 
 
4.3. General procedure for the synthesis of product 8c. 
To a stirred solution of ester hydrochloride as amine (1.1 equiv, 
0.5 mmol) in EtOH (3 mL) was added pyridoxal hydroclorhide (1 
equiv, 0.5 mmol). After, Et3N (2 equiv, 140 µL), dipolarophile (1 
equiv, 0.5 mmol) and AgOAc (5 mol%). The reaction mixture was 
stirred overnight at 70 °C. The solvent was removed under reduced 
pressure. The crude mixture was extracted with ethyl acetate and was 
washed with brine. The organic phase was dried (MgSO4) and after 
filtration and evaporation, the corresponding pyrrolidines were 
obtained without purification. 
 
4.3.1. (1R*,3S*,3aR*,6aS*)-Methyl 5-benzyl-3-(3-hydroxy-5-
(hydroxymethyl)-2-methylpyridin-4-yl)-4,6-
dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8ca): Yellow 
solid, (110 mg, 96% yield). IR (neat) ʋmax: 1211, 1393, 1714, 1745, 
2802, 3264. 1H NMR (300 MHz, CDCl3) δ: 2.26 (s, 3H), 3.50-3.73 
(m, 2H), 3.77 (s, 3H), 4.09 (d, J = 7.5 Hz, 1H), 4.40 (d, J = 14.3 Hz, 
1H), 4.51 (d, J = 14.3 Hz, 1H), 4.90 (d, J = 8.9 Hz, 1H), 7.22-7.28 (m, 
5H), 7.71 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 18.3, 43.1, 47.1, 48.4, 
52.6, 59.3, 61.0, 61.3, 126.1, 128.0, 128.5, 129.0, 132.0, 134.9, 138.6, 
148.6, 152.7, 169.6, 174.8, 175.0. LRMS (EI): m/z = 425 (M+, >1%), 
348 (30), 337 (30), 220 (44), 215 (22), 187 (40), 165 (18), 161 (100), 
150 (31), 139 (17), 91 (95). HRMS (EI): calcd. for C22H23N3O6 [M - 
CH3O, - CO2CH3] 336.1336; found 336.1348. 
 
4.3.2. (1R*,3S*,3aR*,6aS*)-Ethyl 1-benzyl-3-(3-hydroxy-5-
(hydroxymethyl)-2-methylpyridin-4-yl)-5-methyl-4,6-
dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8cb): Pale green 
solid, (204 mg, 90% yield). IR (neat) ʋmax: 731, 1096, 1198, 1288, 
1385, 1437, 1702, 1739, 2664, 2942, 3302. 1H NMR (300 MHz, 
CDCl3) δ: 1.38 (t, J = 7.1 Hz, 3H),  2.78 (s, 3H), 2.32 (s, 3H), 3.10 (d, 
J = 13.8 Hz, 1H), 3.50 (d, J = 7.9 Hz, 1H), 3.69 (d, J = 13.9 Hz, 1H), 
3.98 (t, J = 8.6 Hz, 1H), 4.34 (q, J = 7.0 Hz, 2H), 4.63 (q, J = 13.2 Hz, 
2H), 5.34 (d, J = 9.8 Hz, 1H), 7.17-7.28 (m, 5H), 7.74 (s, 1H). 13C 
NMR (75 MHz, CDCl3) δ: 14.1, 17.9, 25.1, 40.5, 48.5, 53.7, 57.0, 
61.0, 62.4, 71.1, 127.9, 128.1, 129.4, 129.6, 133.0, 134.2, 137.3, 
147.9, 153.2, 170.1, 174.3, 174.4. LRMS (EI): m/z = 453 (M+, >1%), 
362 (22), 345 (19), 344 (100), 187 (24), 91 (17). HRMS (EI): calcd. 
for [C24H27N3O6] 453.1900; found 453.1922. 
 
4.3.3. (1S*,3R*,3aR*,6aS*)-Ethyl 1,5-dibenzyl-3-(3-hydroxy-5-
(hydroxymethyl)-2-methylpyridin-4-yl)-4,6-
dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (8cc): Pale green 
solid, (225 mg, 85% yield). IR (neat) ʋmax: 702, 1200, 1349, 1397, 
1708, 1736, 2658, 2935, 3298. 1H NMR (300 MHz, CDCl3) δ: 1.35 (t, 
J = 7.1 Hz, 3H), 2.31 (s, 3H), 2.99 (d, J = 14.0 Hz, 1H), 3.48 (d, J = 
7.8 Hz, 1H), 3.72 (d, J = 13.8 Hz, 1H), 3.95 (t, J = 8.3 Hz, 1H), 4.34-
4.36 (m, 1H), 4.53 (d, J = 14.0 Hz, 1H), 5.27 (d, J = 9.7 Hz, 1H), 7.14-
7.34 (m, 10H), 7.81 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 14.0, 40.9, 
43.1, 48.1, 53.8, 57.1, 59.4, 62.7, 71.5, 128.1, 128.6, 128.7, 129.1, 
129.2, 129.4, 130.0, 134.3, 134.6, 135.7, 137.8, 142.2, 155.9, 170.1, 
173.5, 173.9. LRMS (EI): m/z = 529 (M+, >1%), 438 (14), 421 (26), 
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420 (100), 187 (26), 91 (65). HRMS (EI): calcd. for C30H31N3O6 [M 
- CH3O] 498.2029; found 498.2026. 
 
4.3.4. (2R*,4S*,5R*)-Diethyl 2-benzyl-5-(3-hydroxy-5-
(hydroxymethyl)-2-methylpyridin-4-yl)pyrrolidine-2,4-dicarboxylate 
(8cd): Yellow oil, (203 mg, 92% yield). IR (neat) ʋmax: 702, 1029, 
1189, 1378, 1735, 2664, 2981, 3322. 1H NMR (300 MHz, CDCl3) δ: 
0.81 (t, J = 7.2 Hz, 3H), 1.27 (t, J = 7.2 Hz, 3H), 2.27-2.42 (m, 4H), 
2.90-2.99 (m, 2H), 3.39 (d, J = 13.7 Hz, 1H), 3.52 (td, J = 8.3, 4.6 Hz, 
1H), 3.70 (qd, J = 7.2, 2.5 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 4.50 (d, 
J = 13.0 Hz, 1H), 4.62 (d, J = 13.0 Hz, 1H), 5.19 (d, J = 8.6 Hz, 1H), 
6.87-7.39 (m, 5H), 7.68 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 13.6, 
14.1, 16.2, 38.5, 44.4, 47.6, 59.7, 59.9, 61.4, 61.9, 69.6, 127.8, 129.1, 
129.1, 129.7, 132.1, 132.4, 135.0, 135.3, 154.9, 171.3, 173.9. LRMS 
(EI): m/z = 442 (M+, >1%), 351 (23), 333 (53), 323 (31), 305 (100), 
287 (62), 259 (17), 91 (41). HRMS (EI): calcd. for C24H30N2O6 [M - 
CH3O, - OH] 394.1534; found 394.1529. 
 
4.4. General procedure for the synthesis of products 8d. 
8da-8db: to a stirred solution of ester hydrochloride as amine (1.1 
equiv, 0.6 mmol) in toluene (2 mL) was added 5-formyluracile (1 
equiv, 0.5 mmol) and Et3N (1.1 equiv). After that, dipolarophile (1.0 
equiv) and AgOAc (5 mol%). The reaction mixture was stirred 
overnight at room temperature. The solvent was removed under 
reduced pressure. The crude mixture was filtrated through celite with 
warm EtOH to furnish the corresponding product. To remove the 
ammonium salt, it was washed with DCM. 
8dc-8de: to a stirred solution of free amine ester (1 equiv was 
previously isolated: 1 equiv of the corresponding hydrochloride with 
1.3 equiv K2CO3, in a mixture of AcOEt/H2O during 1h. It was washed 
with water and the organic fase evaporated), in toluene (2 mL) was 
added 5-formyluracile (1 equiv, 0.5 mmol). After that, dipolarophile 
(1.0 equiv, 0.5 mmol) and AgOAc (5 mol%). The solvent was 
removed under reduced pressure. The crude mixture was filtrated 
through celite with warm EtOH to furnish the corresponding product. 
 
4.4.1. (1S*,3R*,3aS*,6aR*)-Methyl 3-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-
c]pyrrole-1-carboxylate (8da): Pale yellow solid, (132 mg, 82% 
yield). IR (neat) ʋmax: 1098, 1223, 1439, 1694, 1741, 2978. 1H NMR 
(300 MHz, DMSO-d6) δ: 2.66 (s, 3H), 3.39-3.44 (m, 1H), 3.53-3.56 
(m, 1H), 3.67 (s, 3H), 3.92 (d, J = 7.1 Hz, 1H), 4.32 (d, J = 8.7 Hz, 
1H), 7.19-7.27 (m, 4H). 13C NMR (75 MHz, DMSO-d6) δ: 24.6, 48.0, 
49.1, 51.7, 61.0, 63.0, 127.4, 127.5, 128.0, 138.7, 171.8, 175.5, 176.9. 
LRMS (EI): m/z = 322 (M+, >1%), 307 (30), 289 (46), 263 (69), 259 
(17), 211 (93), 206 (51), 204 (41), 178 (24), 151 (93), 121 (46), 107 
(28), 44 (100). LRMS (EI): calcd. for [C13H14N4O6] 322.0913; found 
322.0924. 
 
4.4.2. (1S*,3R*,3aS*,6aR*)-Methyl 5-benzyl-3-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-
1-carboxylate (8db): Pale yellow solid, (175 mg, 88% yield). IR (neat) 
ʋmax: 1157, 1211, 1400, 1445, 1659, 1693, 1740, 3029. 1H NMR (300 
MHz, DMSO-d6) δ: 3.42 (d, J = 3.4 Hz, 1H), 3.46 (d, J = 8.3 Hz, 1H), 
3.64 (d, J = 3.4 Hz, 1H), 3.67 (s, 3H), 3.97 (dd, J = 7.1, 4.2 Hz, 1H), 
4.35 (dd, J = 7.1, 4.2 Hz, 1H), 4.41 (d, J = 4.0 Hz, 2H), 7.16-7.36 (m, 
8H). 13C NMR (75 MHz, DMSO-d6) δ: 41.3, 47.6, 48.6, 51.4, 60.9, 
62.7, 127.1, 127.3, 127.6, 128.2, 135.7, 138.2, 170.4, 174.9, 176.4. 
LRMS (EI): m/z = 398 (M+, >1%), 383 (3), 365 (38), 339 (33), 211 
(100), 206 (23), 204 (32), 187 (15), 151 (70), 106 (17), 91 (75). HRMS 
(EI): calcd. for C19H18N4O6 [M - H+] 397.1158; found 397.1148. 
 
4.4.3. (1S*,3R*,3aS*,6aR*)-Ethyl 1-benzyl-3-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-
c]pyrrole-1-carboxylate (8dc): Grey solid, (198 mg, 93% yield). IR 
(neat) ʋmax: 1098, 1436, 1678, 1697, 3031. 1H NMR (300 MHz, 
DMSO-d6) δ: 1.24 (t, J = 7.1 Hz, 3H), 2.65 (s, 3H), 2.89 (d, J = 6.7 
Hz, 1H), 3.00 (d, J = 13.9 Hz, 1H), 3.16 (d, J = 14.0 Hz, 1H), 3.45-
3.54 (m, 2H), 4.01-4.14 (m, 2H), 4.51 (d, J = 8.5 Hz, 1H), 7.11-7.23 
(m, 8H), 7.39 (s, 1H). 13C NMR (75 MHz, DMSO-d6) δ: 15.2, 25.9, 
50.5, 57.1, 57.6, 62.0, 62.2, 72.9, 126.6, 127.9, 128.1, 129.3, 129.6, 
129.8, 130.2, 130.5, 131.4, 137.6, 165.8, 171.8, 177.1, 177.3. LRMS 
(EI): m/z = 426 (M+, <1%), 353 (11), 336 (16), 335 (100), 289 (14), 
206 (8), 91 (16). Elemental Analysis required for C21H22N4O6: C 
59.20, H 5.20, N 13.10%; found: C 59.40, H 5.00, N 12.85%. 
 
4.4.4. (1S*,3R*,3aS*,6aR*)-Ethyl 1,5-dibenzyl-3-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-
1-carboxylate (8dd): Yellow solid, (240 mg, 96% yield). IR (neat) 
ʋmax: 1199, 1400, 1674, 1703, 3031. 1H NMR (300 MHz, DMSO-d6) 
δ: 1.24 (t, J = 7.1 Hz, 3H), 3.09 (d, J = 13.9 Hz, 1H), 3.24 (d, J = 14.0 
Hz, 1H), 3.57-3.68 (m, 2H), 4.04-4.12 (m, 2H), 4.37 (d, J = 14.0 Hz, 
1H), 4.47 (d, J = 14.0 Hz, 1H), 4.61 (d, J = 8.5 Hz, 1H), 7.16-7.31 (m, 
14H). 13C NMR (75 MHz, DMSO-d6) δ: 14.3, 42.1, 48.9, 55.6, 55.8, 
61.2, 71.7, 127.1, 127.6, 127.7, 128.6, 128.8, 129.7, 130.5, 136.6, 
136.2, 139.1, 151.5, 164.7, 170.8, 175.7, 176.1. LRMS (EI): m/z = 502 
(M+, <1%), 429 (9), 412 (23), 411 (100), 365 (9), 91 (63). Elemental 
Analysis required for C27H26N4O6: C 64.50, H 5.20, N 11.15%; found 
C 64.65, H 5.10, N 11.50%. 
 
4.4.5. (2R*,4S*,5R*)- Ethyl 4-methyl 2-benzyl-5-(2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)pyrrolidine-2,4-dicarboxylate (8de): Pale 
yellow solid, (180 mg, 90% yield). IR (neat) ʋmax: 1202, 1438, 1676, 
1719, 2977, 3061. 1H NMR (300 MHz, DMSO-d6) δ: 1.18 (t, J = 7.1 
Hz, 3H), 2.09 (dd, J = 13.9 Hz, 1H), 2.46 (dd, J = 14.0 Hz, 1H), 2.86-
3.02 (m, 2H), 3.14-3.21 (m, 1H), 3.38 (s, 3H), 4.04-4.11 (m, 2H),  4.39 
(d, J = 8.5 Hz, 1H), 7.20-7.28 (m, 8H), 7.39 (s, 1H). 13C NMR (75 
MHz, DMSO-d6) δ: 8.9, 14.5, 45.9, 47.3, 51.6, 56.8, 60.9, 69.1, 111.9, 
127.0, 128.4, 130.3, 137.4, 138.2, 151.3, 164.1, 173.1, 174.7. LRMS 
(EI): m/z = 401 (M+, <1%), 328 (19), 311 (15), 310 (100), 232 (23), 
211 (7), 204 (8), 91 (27). HRMS (EI): calcd. for C20H23N3O6 [M - 
CO2CH3], 342.1460; found 342.1454. 
 
4.5. General procedure for the synthesis of product 14dc. 
Finely powdered sodium borohydride (6 equiv, 1.3 mmol) was 
suspended in THF (4 mL) in presence of the respective ester (100 mg, 
0.2 mmol) during a period of 15 minutes under reflux (70 °C) and 
stirring. Then methanol (0.45 mL) was added dropwise during a period 
of 5 minutes and effervescence was observed. Stirring and reflux were 
maintained during a period of 10 h. After the end of the reaction, the 
alcohol was cooled to room temperature and quenched with a saturated 
solution of NH4Cl. For purification the organic layer was separated 
and the aqueous phase extracted with DCM. The organic phase was 
dried (MgSO4) and concentrated under low pressure to give the 
corresponding triol 14dc. 
4.5.1. 5-[(2R*,3R*,4R*,5S*)-5-Benzyl-3,4,5-tris(hydroxymethyl)-
pyrrolidin-2-yl]pyrimidine-2,4(1H,3H)-dione (14dc): Pale yellow 
 7 
solid, (65 mg, 80% yield). IR (neat) ʋmax: 702, 1098, 1454, 1698, 1775, 
2926, 3390. 1H NMR (300 MHz, DMSO-d6) δ: 2.42 (dd, J = 13.2, 7.5 
Hz, 1H), 2.55-2.59 (m, 1H), 2.64-2.67 (m, 3H), 2.81-2.84 (m, 1H), 
3.03 (d, J = 10.5 Hz, 1H), 3.15-3.18 (m, 1H), 3.25 (td, J = 11.3, 10.5, 
5.1 Hz, 4H), 3.45 (dd, J = 11.3, 3.3 Hz, 1H), 4.62 (d, J = 6.1 Hz, 1H), 
4.88-5.07 (m, 3H), 7.20-7.32 (m, 8H). 13C NMR (75 MHz, DMSO-d6) 
δ: 34.8, 40.4, 54.6, 59.6, 60.5, 63.0, 66.0, 126.3, 126.7, 128.6, 128.9, 
129.5, 129.6, 138.7, 140.1. LRMS (EI): m/z = 361 (M+, <1%), 164 
(29), 120 (21), 117 (37), 105 (13), 91 (100), 70 (25). HRMS (EI): 
calcd. for C18H23N3O5 [M – 2xCH2O – H2O]: 282.1249; found 
282.1260. 
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